Pharma News

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration FDA has approved Dupixent dupilumab for the treatment of adult patients with bullous pemphigoid.

Orion’s collaboration partner Bayer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor , plus androgen deprivation therapy for marketing authorisation in the European Union for the treatment of patients with metastatic hormone-sensitive prostate cancer

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system. This treatment modifies endogenous immune cells such that they can specifically target and eliminate B lymphocytes, which are here the origin of autoimmunity.

The anti-aging drug Rapamycin has the same life-extending effect as eating less, according to new research from the University of East Anglia and University of Glasgow

In a landmark development, Gilead Sciences announced today that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), the first injectable pre-exposure prophylaxis (PrEP) for HIV prevention requiring just two doses per year.

Fresenius Kabi has issued an urgent nationwide recall of a specific lot of its Ivenix Large-Volume Pump (LVP) Blood Products Administration Sets, following the discovery of a manufacturing defect that could lead to serious or even fatal consequences.

Genetic material shed by tumors can be detected in the bloodstream three years prior to cancer diagnosis, according to a study led by investigators at the Ludwig Center at Johns Hopkins, Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and the Johns Hopkins Bloomberg School of Public Health.

Scientists have discovered a unique class of small antibodies that are strongly protective against a wide range of SARS coronaviruses, including SARS-CoV-1 and numerous early and recent SARS-CoV-2 variants.

GlobalData’s latest analysis reveals a significant shift in the pharmaceutical landscape: in 2024, large pharmaceutical companies sourced an unprecedented 28% of their innovative drug candidates through licensing agreements with Chinese biopharma firms—the highest proportion ever recorded.